Correspondence

Tuberculosis — drugs in the 2016 development pipeline

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    et al. Tuberculosis. Nat. Rev. Dis. Primers 2, 16076 (2016).

  2. 2.

    et al. Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins. Science 348, 1106–1112 (2015).

  3. 3.

    & First clinical trial with the novel drug candidate PBTZ169: expected results and surprises [abstract 56]. Tuberculosis2016.org (2016).

  4. 4.

    [No authors listed.] New TB compound to be developed for Pan-TB regimen. StopTB (2016).

  5. 5.

    Sutezolid and SQ-109 update. Talk presented at the Clinical Path to TB Drug Regimens (CPTR) Workshop, May 2016 (2016).

  6. 6.

    et al. Effectiveness and safety of a chemotherapy regimen that includes SQ109 in pulmonary tuberculosis patients with MDR-TB. Talk presented at the National Scientific and Practical Conference of Phthisiologists, Moscow (2016).

  7. 7.

    et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomized controlled trial. Lancet Infect. Dis. 17, 39–49 (2016).

  8. 8.

    & Finding the right dose of rifampicin, and the right dose of optimism. Lancet Infect. Dis. 17, 2–3 (2016).

  9. 9.

    US National Library of Medicine. ClinicalTrials.gov (2016).

Download references

Author information

Affiliations

  1. STOP TB Partnership's Working Group on New TB Drugs, 24th Floor, 40 Wall Street, New York, New York 10005, USA.

    • Barbara E. Laughon
  2. Sequella, Inc., Suite 200, 9610 Medical Center Drive, Rockville, Maryland 20850, USA.

    • Carol A. Nacy

Authors

  1. Search for Barbara E. Laughon in:

  2. Search for Carol A. Nacy in:

Competing interests

C.A.N. is the Founder and CEO of Sequella, Inc., which is the commercial developer of sutezolid and SQ109. B.E.L. declares no competing interests.

Corresponding author

Correspondence to Barbara E. Laughon.